More MS news articles for Jan 2002

Biogen to Provide Neurologists With Educational Tools and Internet Services Through Salu(R), Inc.'s NeuroHub

http://globalarchive.ft.com/globalarchive/article.html?id=020110005873&query=sclerosis

Jan 10, 2002
PR Newswire - USA;

Salu(R), Inc., the developer of Medical Specialty Hubs(TM) that provide Web-based tools and services to help physician-specialists improve patient care and practice efficiency, announced today that Biogen, Inc. , the manufacturer of AVONEX(R) (Interferon beta-1a), the world's leading treatment for multiple sclerosis (MS), will participate in NeuroHub, Salu's Medical Specialty Hub(TM) for neurologists. Under the terms of the multi-year agreement, Biogen will offer neurologists access to NeuroHub Web capabilities. This will help Biogen to reach neurologists and their patients with information and educational materials about MS and AVONEX(R), as well as information about any forthcoming drugs.

"Biogen's leadership in the multiple sclerosis therapeutic area is a great fit with Salu because more than half of U.S. office-based neurologists are enrolled in NeuroHub," said Jim Steeb, President and CEO of Salu. "With this agreement, Biogen can integrate NeuroHub's flexible and customizable tools and services into its overall physician communication initiatives," Steeb added.

"We believe the Internet is playing an increasingly important role in patient education, and through our relationship with Salu we are pleased to make these communications tools available to neurologists and people with MS," said Rob Perez, Vice President, CNS Business Unit of Biogen. "We value Salu's dedication and focus on specialists -- in this case neurologists -- because effective relationships with these physicians and their patients are of tremendous importance to us," added Perez.

The partnership will provide Biogen with a direct business channel to reach top-prescribing neurologists and their patients and provide them with educational information and programs. The agreement offers Biogen a set of services, including the creation of a Partner Resource Center on NeuroHub that provides physicians with new study information, drug updates, research information, online continuing medical education (CME) courses, patient education materials, and more.

The agreement also will provide Biogen with broader exposure for its current Internet initiatives, including its MS ActiveSource(TM) Web site, that offer MS patients and their care partners support and information to help them better manage the disease. Information about MS research and educational events, interactive learning tools, disease and therapy information and community support can be found on the MS ActiveSource(TM) Web site. Through the agreement with Salu, MS patients will be able to access Biogen's MS ActiveSource(TM) Web site directly from their doctor's Web site along with other important disease and therapy information.

Salu provides a range of specialty-specific products and services to physician-specialists -- including the development of individualized Web sites -- to help its members deliver quality care, operate their practices more efficiently and increase revenue. Salu field representatives visit with specialists and provide them -- from one integrated source -- easy access to 500 proprietary tools and business consultation resources including a handheld prescription writer and a full range of products and services offered through business and pharmaceutical partners, such as Biogen. In addition, Salu's Patient Center, a secure site for physician-patient communication, combines health education, medical reference materials and secure messaging.

Salu has partnerships with several leading pharmaceutical companies including AstraZeneca, Elan Pharmaceuticals and Organon. Salu is also in discussions with other pharmaceutical companies focusing on neurology, as well as companies with products in various specialty categories including dermatology, gastroenterology and reproductive medicine.

About Salu(R), Inc.

Salu(R), Inc. is based on the premise that medical specialists have distinctly different needs. Salu's unique Medical Specialty Hubs(TM) offer customized tools and services to help specialists increase practice efficiency and improve patient care. Today, a significant percentage of the nation's allergists, dermatologists, neurologists and cardiologists access Salu Medical Specialty Hubs to run more efficient, profitable practices. Salu provides strategic partners with access to an organized and efficient marketplace of specialists and their practices. Additionally, the Salu Medical Specialty Hubs provide an efficient and complementary channel for pharmaceutical companies to access specialists and their patients. NeuroHub, a division of Salu, Inc., provides an efficient business channel to neurologists and pain medicine specialists and serves well over 4,000 neurologists through online and offline services.

Salu is a leading sponsor of the eHealth Ethics Initiative developed by the Internet Healthcare Coalition and the recipient of a 2001 eHealthcare Leadership Award for Best Site Design among physician/clinical focused sites. The distinction was awarded by eHealthcare Strategy & Trends, a leading Internet publication and online resource. Potential partners and interested physician-specialists can learn more about Salu by visiting http://www.salu.com/ or calling 888-288-SALU.

About Biogen

Biogen, Inc., winner of the U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human health care through genetic engineering. Headquartered in Cambridge, Mass., the company's revenues are generated from international sales of AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen's research and development activities are focused on novel products to treat inflammatory and autoimmune diseases, neurological diseases, cancer, fibrosis and congestive heart failure. The company maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy. For copies of press releases and additional information about the company, please consult Biogen's home page on the World Wide Web at http://www.biogen.com/ .

Contact: Jeremiah Hall of Ogilvy PR Worldwide, +1-415-677-2720, for Salu, Inc.
Website: http://www.biogen.com/
Website: http://www.salu.com/
 

World Reporter All Material Subject to Copyright